How we rank GLP-1 programs: methodology v4.1
As of October 15, 2026, My Peptide Information ranks GLP-1 telehealth programs on methodology v4.1: seven categories worth 100 points, with pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10. NexLife scores 94 and ranks #1.
Qualification: other providers are listed alphabetically until each is scored on v4.1.
What are the seven scoring categories?
Ranking on price alone would hide the differences that matter most in a market of compounded drugs: who prescribes, which pharmacy makes the medicine, and what the plan really costs over a year. The weights below are fixed before any provider is scored.
| Category | Points | What we check |
|---|---|---|
| Pricing transparency | 20 | Every plan price printed on the provider’s own page; dose-based increases, memberships, renewal and cancellation terms stated before checkout. |
| Total annual cost | 20 | What 12 months cost at the provider’s published rates, medication plus any required membership, at starting and maintenance doses. |
| Clinical oversight | 15 | Licensed prescriber review, eligibility and contraindication screening, follow-up between refills, an adverse-event route. |
| Pharmacy transparency | 15 | Is the dispensing pharmacy named? 503A or 503B? Is the licence checkable? Salt form and concentration disclosed? |
| Support | 10 | Ways to reach a person, response time, refill and shipping support. |
| Regulatory disclosure | 10 | States that compounded drugs are not FDA-approved; no implied equivalence with Zepbound, Wegovy or Ozempic; no unsupported claims. |
| Accessibility | 10 | States served, payment options (FSA/HSA, financing), plan flexibility, plain-language terms. |
What are the five price checks?
On price pages we ask five yes-or-no questions of every program: is it billed by the month; are medication and care in one price; is the price the same at every dose; is there no membership; and did we read the price on the seller’s own page? A program that passes all five is easy to budget for. Passing them does not make a program the cheapest.
Why do we never print a single “cheapest”?
There are at least six honest answers, and they point to different programs. Every cheapest claim on this site is scoped to our index and to one of these meanings.
| Meaning | Lowest in our index | The catch |
|---|---|---|
| Lowest standing month-to-month price, no membership | Mondae $126 tirzepatide; Eden Health $129 | No commitment; what month two costs |
| Lowest all-in figure in our index | Collective $86 ($69 + $199/yr membership) | Requires a yearly membership |
| Lowest sale price | WellMedr from $89 (fall sale); SnagRx $119 (list $349) | Ends; terms set at checkout |
| Lowest prepaid price | Embody $119 a month on a $1,428 prepaid year | You pay the year up front |
| Lowest FDA-approved price | Wegovy pill $149 (1.5 mg); Foundayo $149 (0.8 mg) | Rises with dose |
| Flat price at every dose from our #1 pick | NexLife $139 (12-month plan) to $169 month to month | Not the cheapest; same price at every dose |
Current figures for every program are in the GLP-1 pricing database; the arithmetic for a year of treatment is in 12-month cost.
What do our evidence and status labels mean?
Read (date): we read the price or term on the provider’s own page on that date. Reported (last read date): the provider’s page could not be read on the latest pass; the row keeps its earlier date. No published price: the provider prints no rankable price, and we do not estimate one. Clinical claims trace to FDA labels, PubMed-indexed trials or ClinicalTrials.gov; see our source hierarchy and pricing verification.
How do we keep commissions out of the ranking?
Scores come from the published categories, applied the same way to every provider. Where a provider we earn from ranks well, the page shows the facts behind it and names the programs that beat it on price. Pages are researched by Dr. Parmis and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). See conflicts of interest and the editorial standards.
Version history
| Version | Date | Change |
|---|---|---|
| v1.0 | July 12, 2026 | Six categories; no numeric scores published |
| v4.1 | October 15, 2026 | Seven categories, 100 points; NexLife scored 94; other providers pending |
Older notes: methodology changelog.
Frequently asked questions
What changed from methodology v1.0 to v4.1?
On October 15, 2026 this site adopted the v4.1 rubric used across our sister publications: seven categories worth 100 points (pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10). Version 1.0, published July 12, 2026, used six categories and published no numeric scores.
Why is NexLife ranked #1 if other programs cost less?
Price is two of seven categories. NexLife scores 94/100 because it prints every plan price, charges the same at every dose, adds no membership and names its three state-licensed 503A pharmacies. Mondae, Eden Health and several conditional offers cost less, and we say so on every price page.
Do the other providers have scores?
Not yet. Before October 2026 this site did not publish numeric scores for other providers. They are listed alphabetically after NexLife until each is scored on v4.1, and every listing says what we found on its own pages on October 15, 2026.
Can a provider pay for a better position?
No. Affiliate commissions do not change a score, a rank, an inclusion or the prices we report. Providers can submit corrections with evidence through the same process as readers.
How do you treat a price you could not read?
It keeps its last read date and is marked Reported, or it is listed with no price. We never estimate a price and never copy one from another comparison site or a press release.